Novartis AG Common Stock (NVS)

Total Costs & Expenses

$38.64B

TTM · Period ending: · USD

NVS logo

NVS Total Costs & Expenses

Latest reported$38.64B
NVS TTM Total Costs & Expenses ($19.82B → $38.64B)
High-resolution chart · PNG

NVS total costs & expenses history

Trailing twelve months (TTM) · USD. Each value covers four complete reported quarters.

Novartis AG Common Stock Total Costs & Expenses — Trailing twelve months (TTM) (USD)
Period endingTotal Costs & Expenses (USD)
38,642,886,000
38,932,254,000
38,600,254,000
38,814,000,000
38,502,000,000
37,388,000,000
37,178,000,000
36,344,000,000
37,129,000,000
37,209,000,000
36,891,000,000
38,835,000,000
37,462,000,000
39,381,000,000
40,914,000,000
40,736,000,000
41,913,000,000
40,871,000,000
41,188,000,000
40,614,000,000
40,606,000,000
40,061,000,000
39,746,000,000
40,253,000,000
40,251,000,000
40,342,000,000
39,591,000,000
41,063,000,000
40,086,000,000
39,947,000,000
39,526,000,000
38,255,000,000
39,443,000,000
40,435,000,000
41,506,000,000
41,563,000,000
41,300,000,000
41,672,000,000
41,168,000,000
41,144,000,000
41,323,000,000
41,352,000,000
41,410,000,000
41,286,000,000
41,596,000,000
41,746,000,000
42,545,000,000
44,532,000,000
44,319,000,000
43,801,000,000
44,895,000,000
44,492,000,000
45,235,000,000
46,421,000,000
46,288,000,000
47,380,000,000
48,372,000,000
48,740,000,000
48,377,000,000
46,695,000,000
44,845,000,000
42,004,000,000
40,035,000,000
38,546,000,000
36,969,000,000
36,387,000,000
35,121,000,000
33,281,000,000
33,320,000,000
33,471,000,000
33,620,000,000
34,816,000,000
33,897,000,000
32,539,000,000
31,850,000,000
29,706,000,000
28,975,000,000
28,084,000,000
27,137,000,000
26,682,000,000
26,238,000,000
25,979,000,000
25,548,000,000
24,327,000,000
23,066,000,000
22,224,000,000
21,708,000,000
20,788,000,000
20,189,000,000
19,750,000,000
18,975,000,000
19,768,000,000
18,844,000,000
18,260,000,000
18,748,000,000
17,969,000,000
19,728,000,000
18,913,000,000
18,495,000,000
19,318,000,000
Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.